Related Experiment Video

Updated: Jun 17, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

[Clinical and pathological topics of multiple sclerosis]

Hans Lassmann1

  • 1Center for Brain Research, Medical University of Vienna, Spitalgasse 4, A-1090 Wien, Austria.

Rinsho Shinkeigaku = Clinical Neurology
|December 25, 2009
PubMed

Insights

Therapeutic options for progressive multiple sclerosis (MS) are limited due to poor understanding of its pathophysiology. This review highlights distinct progressive MS pathology, emphasizing inflammation-induced mitochondrial injury as a key target for future treatments.

Area of Science:

  • Neuroimmunology
  • Neuropathology

Context:

  • Limited therapeutic options for progressive multiple sclerosis (MS).
  • Incomplete understanding of progressive MS pathophysiology.
  • Need for targeted treatments addressing distinct pathological features.

Purpose:

  • To review recent findings on the pathophysiology of progressive MS.
  • To identify key differences between relapsing and progressive MS pathology.
  • To inform future therapeutic strategies for progressive MS.

Summary:

  • Progressive MS exhibits unique pathology, including white matter lesion expansion, cortical demyelination, and diffuse normal-appearing white matter injury.
  • Active tissue injury in progressive MS is linked to inflammation, often compartmentalized behind the blood-brain barrier.
  • Inflammation-induced mitochondrial injury is a dominant pathway in progressive MS pathogenesis.

Impact:

  • Identifies critical pathological differences between relapsing and progressive MS.
  • Highlights inflammation-induced mitochondrial injury as a key therapeutic target.
  • Suggests a dual approach of targeting CNS-compartmentalized inflammation and neuroprotection for progressive MS treatment.

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...